What are the side effects of Enasidenib?

In clinical studies of Enasidenib, the most common adverse reactions (≥20%) include nausea, vomiting, diarrhea, increased bilirubin levels and decreased appetite; the most common serious adverse reactions (≥2%) are leukocytosis, diarrhea, nausea, vomiting, decreased appetite, tumor lysis syndrome and differentiation syndrome; severe differentiation syndrome events include fever, acute renal failure, hypoxia, respiratory failure and multiple organ failure.

Overall,43% of patients required dose interruption due to adverse reactions, including differentiation syndrome and leukocytosis; 5% of patients required dose reduction due to adverse reactions; 17% of patients permanently discontinued ensidipine due to adverse reactions, namely leukocytosis. Symptoms of differentiation syndrome, which can be fatal if left untreated, may appear as early as 10 days to 5 months after starting treatment. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptoms resolve. Early recognition and aggressive management of differentiation syndromes are needed to reduce the likelihood of severe illness and death.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.